Comparative study of tailored therapy and dual therapy for Helicobacter pylori infection

A comparative study of tailored therapy guided by genotypic resistance and dual therapy in the eradication treatment of Helicobacter pylori infection: a multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300079253

Enrollment

Unknown

Registered

2023-12-28

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Dual therapy:Dual therapy

Tailored therapy:Tailored therapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients undergoing gastroscopy for various reasons (2) Patients with Hp infection (3) Patients who have not undergone eradication therapy (4) Age 18-75

Exclusion criteria

Exclusion criteria: (1) Proton Pump Inhibitor (PPI) or Potassium Channel Acid Blockers (P-CAB) was taken within two weeks prior to enrollment, bismuth or antibiotics was taken within four weeks prior to enrollment (2) Patients with malignant tumors of the digestive tract (3) Patients who have undergone gastric or esophageal surgery (4) Patients with a combination of serious underlying diseases (5) Patients with previous Hp eradication (6) Patients allergic to the drugs used in this study (7) Pregnant or lactating women (8) Patients unwilling to participate or unable to cooperate with this study

Design outcomes

Primary

Measure	Time frame
Eradication rate of Helicobacter pylori infection;	—

Secondary

Measure	Time frame
Incidence of adverse reactions;Patient compliance;Cost effectiveness;Changes in the diversity of intestinal flora;	—

Countries

China

Contacts

Public ContactSong Zhiqiang

Peking University Third Hospital

szqinputh@163.com+86 189 1019 2576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026